Management of lung transplantation in the COVID-19 era—An international survey
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
; 21(4):1586-1596, 2021.
Article
in English
| EuropePMC | ID: covidwho-2229023
ABSTRACT
It is unknown if solid organ transplant recipients are at higher risk for severe COVID-19. The management of a lung transplantation (LTx) program and the therapeutic strategies to adapt the immunosuppressive regimen and antiviral measures is a major issue in the COVID-19 era, but little is known about worldwide practice. We sent out to 180 LTx centers worldwide in June 2020 a survey with 63 questions, both regarding the management of a LTx program in the COVID-19 era and the therapeutic strategies to treat COVID-19 LTx recipients. We received a total of 78 responses from 15 countries. Among participants, 81% declared a reduction of the activity and 47% restricted LTx for urgent cases only. Sixteen centers observed deaths on waiting listed patients and eight centers performed LTx for COVID-19 disease. In 62% of the centers, COVID-19 was diagnosed in LTx recipients, most of them not severe cases. The most common immunosuppressive management included a decreased dose or pausing of the cell cycle inhibitors. Remdesivir, hydroxychloroquine, and azithromycin were the most proposed antiviral strategies. Most of the centers have been affected by the COVID-19 pandemic and proposed an active therapeutic strategy to treat LTx recipients with COVID-19.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS